Implications for Managed Care Pharmacy from the FDA Reauthorization Act of 2017 (FDARA)
Webinar Recorded on August 15, 2017
Join AMCP for a deep-dive of the FDA Reauthorization Act of 2017 (FDARA) which authorizes user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilars. This webinar will highlight the areas of greatest impact to managed care pharmacy including the FDA’s commitment to enhance the use of real-world evidence in drug development, implement strategies to increase generic competition in the marketplace, and advance the pharmacovigilance of medications. Learn how FDARA will impact your organization and how to be prepared!
- Stephen Northrup, MPA
Rampy Northrup LLC